CAM
PNT

Cormorant Asset Management’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Cormorant Asset Management’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-500,000
Closed -$5.25M – 128
2021
Q1 		$5.25M Hold
500,000
– – 0.12% 93
2020
Q4 		$6.97M Hold
500,000
– – 0.17% 78
2020
Q3 		$7.19M Buy
+500,000
New +$6.82M 0.28% 66

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Cormorant Asset Management's PNT Position: Q2 2021 in Review

Cormorant Asset Management sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q2 2021, closing a stake of 500,000 shares — an estimated $5.25M sold.

Cormorant Asset Management first reported a position in PNT in Q3 2020 and held it in 3 quarters. The position peaked at $7.19M in Q3 2020. 21 funds tracked by Wall St. Rank hold PNT as of Q2 2021.

  • Cormorant Asset Management reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Cormorant Asset Management sold 500,000 POINT Biopharma Global Inc. Common Stock shares in Q2 2021, an estimated $5.25M.
  • Cormorant Asset Management first reported a position in POINT Biopharma Global Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Cormorant Asset Management's POINT Biopharma Global Inc. Common Stock position peaked at $7.19M in Q3 2020.
  • 21 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q2 2021.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.